Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
By Constanze Drechsel
Myasthenia gravis is an autoimmune disease affecting 14-20/100,000 people in the U.S.1 and 1-9/100,000 people in Europe.2 The sad truth is that most of those afflicted go undiagnosed. Myasthenia gravis causes severe muscle...
By Anne Hartenhauer
More than 90% of patients with signs and symptoms of myasthenia gravis can be readily detected and treated with a range of effective therapies. The key to early diagnosis and treatment that can lead to remission is the selection...
By Anne Hartenhauer
“Myasthenia gravis is eminently treatable,” say researchers at UCL’s Institute of Neurology1. Yet clinicians still find it challenging to detect and manage. In a new webinar entitled “Autoantibodies in Myasthenia Gravis,” Dr. Jan...
By Anne Hartenhauer
Myasthenia gravis is an autoimmune disease with an estimated prevalence of 14-20/100,000 population in the U.S.1 and 1-9 /100,000 population in Europe.2 Many affected individuals go undiagnosed. Myasthenia gravis can cause severe...